Cancer Research and Treatment

Original Articles

Breast cancer

Efficacy of Limited Dose Modifications for Palbociclib-Related Grade 3 Neutropenia in Hormone Receptor–Positive Metastatic Breast Cancer: Seul-Gi Kim, Min Hwan Kim, Sejung Park, Gun Min Kim, Jee Hung Kim, Jee Ye Kim, Hyung Seok Park, Seho Park, Byeong Woo Park, Seung Il Kim, Jung Hwan Ji, Joon Jeong, Kabsoo Shin, Jieun Lee, Hyung-Don Kim, Kyung Hae Jung, Joohyuk Sohn; Cancer Res Treat. 2023;55(4):1198-1209. Published online April 11, 2023; DOI: https://doi.org/10.4143/crt.2022.1543

Abstract PDF Supplementary Material PubReader ePub

Purpose
Frequent neutropenia hinders uninterrupted palbociclib treatment in patients with hormone receptor (HR)–positive breast cancer. We compared the efficacy outcomes in multicenter cohorts of patients with metastatic breast cancer (mBC) receiving palbociclib following conventional dose modification or limited modified schemes for afebrile grade 3 neutropenia.
Materials and Methods
Patients with HR-positive, human epidermal growth factor receptor 2–negative mBC (n=434) receiving palbociclib with letrozole as first-line therapy were analyzed and classified based on neutropenia grade and afebrile grade 3 neutropenia management as follows: group 1 (maintained palbociclib dose, limited scheme), group 2 (dose delay or reduction, conventional scheme), group 3 (no afebrile grade 3 neutropenia event), and group 4 (grade 4 neutropenia event). The primary and secondary endpoints were progression-free survival (PFS) between groups 1 and 2 and PFS, overall survival, and safety profiles among all groups.
Results
During follow-up (median 23.7 months), group 1 (2-year PFS, 67.9%) showed significantly longer PFS than did group 2 (2-year PFS, 55.3%; p=0.036), maintained across all subgroups, and upon adjustment of the factors. Febrile neutropenia occurred in one and two patients of group 1 and group 2, respectively, without mortality.
Conclusion
Limited dose modification for palbociclib-related grade 3 neutropenia may lead to longer PFS, without increasing toxicity, than the conventional dose scheme.

Citations

Citations to this article as recorded by

Efficacy and Safety of Cyclin-Dependent Kinase 4/6 Inhibitors in Patients with Breast Cancer: A Systematic Review and Meta-analysis of Randomized Controlled Trials and Real-World Studies
Hui-Chen Su, Ho-Wei Lin, Ka-Wai Tam
Targeted Oncology.2025; 20(1): 71. CrossRef
Palbociclib Is Safe for Breast Cancer Patients With Mild Hepatic Impairment: A Multicenter Retrospective Study Using Real‐World Data
Alieke K. Bos, Annelieke E.C.A.B. Willemsen, Loes E. Visser, Lennart J. Stoker, Jurjen S. Kingma, Mirjam K. Rommers, Emile M. Kuck, Paul D. van der Linden, Merel van Nuland
Clinical Pharmacology & Therapeutics.2025;[Epub] CrossRef
Palbociclib

Reactions Weekly.2023; 1988(1): 138. CrossRef

4,266 View
272 Download
2 Web of Science
3 Crossref

Eflapegrastim versus Pegfilgrastim for Chemotherapy-Induced Neutropenia in Korean and Asian Patients with Early Breast Cancer: Results from the Two Phase III ADVANCE and RECOVER Studies: Yong Wha Moon, Seung Ki Kim, Keun Seok Lee, Moon Hee Lee, Yeon Hee Park, Kyong Hwa Park, Gun Min Kim, Seungtaek Lim, Seung Ah Lee, Jae Duk Choi, Eunhye Baek, Hyesun Han, Seungjae Baek, Seock-Ah Im; Cancer Res Treat. 2023;55(3):766-777. Published online January 19, 2023; DOI: https://doi.org/10.4143/crt.2022.987

Abstract PDF Supplementary Material PubReader ePub

Purpose
We investigated the consistent efficacy and safety of eflapegrastim, a novel long-acting granulocyte-colony stimulating factor (G-CSF), in Koreans and Asians compared with the pooled population of two global phase 3 trials.
Materials and Methods
Two phase 3 trials (ADVANCE and RECOVER) evaluated the efficacy and safety of fixed-dose eflapegrastim (13.2 mg/0.6 mL [3.6 mg G-CSF equivalent]) compared to pegfilgrastim (6 mg based on G-CSF) in breast cancer patients who received neoadjuvant or adjuvant docetaxel/cyclophosphamide. The primary objective was to demonstrate non-inferiority of eflapegrastim compared to pegfilgrastim in mean duration of severe neutropenia (DSN) in cycle 1, in Korean and Asian subpopulations.
Results
Among a total of 643 patients randomized to eflapegrastim (n=314) or pegfilgrastim (n=329), 54 Asians (29 to eflapegrastim and 25 to pegfilgrastim) including 28 Koreans (14 to both eflapegrastim and pegfilgrastim) were enrolled. The primary endpoint, DSN in cycle 1 in the eflapegrastim arm was non-inferior to the pegfilgrastim arm in Koreans and Asians. The DSN difference between the eflapegrastim and pegfilgrastim arms was consistent across populations: –0.120 days (95% confidence interval [CI], –0.227 to –0.016), –0.288 (95% CI, –0.714 to 0.143), and –0.267 (95% CI, –0.697 to 0.110) for pooled population, Koreans and Asians, respectively. There were few treatment-related adverse events that caused discontinuation of eflapegrastim (1.9%) or pegfilgrastim (1.5%) in total and no notable trends or differences across patient populations.
Conclusion
This study may suggest that eflapegrastim showed non-inferior efficacy and similar safety compared to pegfilgrastim in Koreans and Asians, consistently with those of pooled population.

Citations

Citations to this article as recorded by

Comparison of Prophylactic Efficacy of Eflapegrastim and Pegteograstim for Chemotherapy-induced Neutropenia in Pancreatic Cancer Patients Receiving FOLFIRINOX/mFOLFIRINOX
Eui Seon Lee, Min Jung Geum, Jong Hee Ko, Jae Song Kim, Eun Sun Son, Yun Mi Yu
Journal of Korean Society of Health-System Pharmacists.2024; 41(3): 253. CrossRef

4,832 View
274 Download
1 Crossref

Impacts of Subtype on Clinical Feature and Outcome of Male Breast Cancer: Multicenter Study in Korea (KCSG BR16-09): Jieun Lee, Keun Seok Lee, Sung Hoon Sim, Heejung Chae, Joohyuk Sohn, Gun Min Kim, Kyung-Hee Lee, Su Hwan Kang, Kyung Hae Jung, Jae-ho Jeong, Jae Ho Byun, Su-Jin Koh, Kyoung Eun Lee, Seungtaek Lim, Hee Jun Kim, Hye Sung Won, Hyung Soon Park, Guk Jin Lee, Soojung Hong, Sun Kyung Baek, Soon Il Lee, Moon Young Choi, In Sook Woo; Cancer Res Treat. 2023;55(1):123-135. Published online March 24, 2022; DOI: https://doi.org/10.4143/crt.2021.1561

Abstract PDF Supplementary Material PubReader ePub

Purpose
The treatment of male breast cancer (MBC) has been extrapolated from female breast cancer (FBC) because of its rarity despite their different clinicopathologic characteristics. We aimed to investigate the distribution of intrinsic subtypes based on immunohistochemistry, their clinical impact, and treatment pattern in clinical practice through a multicenter study in Korea.
Materials and Methods
We retrospectively analyzed clinical data of 248 MBC patients from 18 institutions across the country from January 1995 to July 2016.
Results
The median age of MBC patients was 63 years (range, 25 to 102 years). Among 148 intrinsic subtype classified patients, 61 (41.2%), 44 (29.7%), 29 (19.5%), and 14 (9.5%) were luminal A, luminal B, human epidermal growth factor receptor 2, and triple-negative breast cancer, respectively. Luminal A subtype showed trends for superior survival compared to other subtypes. Most hormone receptor-positive patients (166 patients, 82.6%) received adjuvant endocrine treatment. Five-year completion of adjuvant endocrine treatment was associated with superior disease-free survival (DFS) in patients classified with an intrinsic subtype (hazard ratio [HR], 0.15; 95% confidence interval [CI], 0.04 to 0.49; p=0.002) and in all patients (HR, 0.16; 95% CI, 0.05 to 0.54; p=0.003).
Conclusion
Distribution of subtypes of MBC was similar to FBC and luminal type A was most common. Overall survival tended to be improved for luminal A subtype, although there was no statistical significance. Completion of adjuvant endocrine treatment was associated with prolonged DFS in intrinsic subtype classified patients. MBC patients tended to receive less treatment. MBC patients should receive standard treatment according to guidelines as FBC patients.

Citations

Citations to this article as recorded by

HER2 expression and pathway status in male breast cancer patients: results of an integrated analysis among 6,150 patients
Boqiang Lyu, Shidi Zhao, Hui Wang, Shouping Gong, Biyuan Wang
Scientific Reports.2025;[Epub] CrossRef
Male breast cancer - a single center experience
Igor Djurisic, Milan Zegarac, Milan Kocic, Vladimir Jokic, Nikola Vucic, Ognjen Petrovic, Nada Santrac, Jovana Koncar, Andjela Ivezic, Srdjan Nikolic
Srpski arhiv za celokupno lekarstvo.2025; 153(1-2): 53. CrossRef
Clinicopathologic Features and Prognoses of Male Patients With Breast Cancer
Meiling Huang, Jingjing Xiao, Changjiao Yan, Rui Ling, Ting Wang
American Journal of Men's Health.2024;[Epub] CrossRef

5,975 View
181 Download
3 Web of Science
3 Crossref

Breast Cancer

Implications of Tamoxifen Resistance in Palbociclib Efficacy for Patients with Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: Subgroup Analyses of KCSG-BR15-10 (YoungPEARL): Jiyun Lee, Seock-Ah Im, Gun Min Kim, Kyung Hae Jung, Seok Yun Kang, In Hae Park, Jee Hyun Kim, Hee Kyung Ahn, Yeon Hee Park; Cancer Res Treat. 2021;53(3):695-702. Published online December 17, 2020; DOI: https://doi.org/10.4143/crt.2020.1246

Abstract PDF PubReader ePub

Purpose
YoungPEARL (KCSG-BR15-10) trial demonstrated a significant progression-free survival (PFS) benefit for premenopausal patients with hormone receptor–positive/human epidermal growth factor receptor 2–negative (HR+/HER2–) metastatic breast cancer (MBC) for palbociclib plus exemestane with ovarian function suppression compared to capecitabine. However, the number of tamoxifen-sensitive premenopausal patients was small because most recurrences occurred early during adjuvant endocrine therapy (ET), with tamoxifen being the only drug used; hence, the data for these patients were limited. Here we present a subgroup analysis according to tamoxifen sensitivity from the YoungPEARL study. Materials and Methods Patients were randomized 1:1 to receive palbociclib+ET (oral exemestane 25 mg/day for 28 days, palbociclib 125 mg/day for 21 days, plus leuprolide 3.75 mg subcutaneously every 4 weeks) or chemotherapy (oral capecitabine 1,250 mg/m2 twice daily for 14 days every 3 weeks). Tamoxifen resistance was defined as: relapse while on adjuvant tamoxifen, relapse within 12 months of completing adjuvant tamoxifen, or progression while on first-line tamoxifen within 6 months for MBC.
Results
In total, 184 patients were randomized and 178 were included in the modified intention-to-treat population. PFS improvement in the palbociclib+ET group was observed in tamoxifen-sensitive patients (hazard ratio, 0.38; 95% confidence interval, 0.12 to 1.19). Furthermore, palbociclib+ET prolonged median PFS compared with capecitabine in tamoxifen-sensitive (20.5 months vs. 12.6 months) and tamoxifen-resistant (20.1 months vs. 14.5 months) patients. Palbociclib+ET demonstrated a higher rate of objective response, disease control, and clinical benefit in tamoxifen-sensitive patients. Conclusion This post hoc exploratory analysis suggests that palbociclib+ET is a promising therapeutic option for premenopausal HR+/HER2– MBC patients irrespective of tamoxifen sensitivity.

Citations

Citations to this article as recorded by

Palbociclib plus endocrine therapy in hormone receptor-positive and HER2 negative metastatic breast cancer: a multicenter real-world study in the northwest of China
Jiao Yang, Bing Zhao, Xiaoling Ling, Donghui Li, Jiuda Zhao, Yonggang Lv, Guangxi Wang, Xinlan Liu, Nanlin Li, Jin Yang
BMC Cancer.2023;[Epub] CrossRef

7,283 View
276 Download
2 Web of Science
1 Crossref

Ramosetron versus Palonosetron in Combination with Aprepitant and Dexamethasone for the Control of Highly-Emetogenic Chemotherapy-Induced Nausea and Vomiting: Jin Hyoung Kang, Jung Hye Kwon, Yun-Gyoo Lee, Keon Uk Park, Ho Jung An, Joohyuk Sohn, Young Mi Seol, Hyunwoo Lee, Hwan-Jung Yun, Jin Seok Ahn, Ji Hyun Yang, Hunho Song, Dong-Hoe Koo, Jin Young Kim, Gun Min Kim, Hwa Jung Kim; Cancer Res Treat. 2020;52(3):907-916. Published online March 18, 2020; DOI: https://doi.org/10.4143/crt.2019.713

Abstract PDF Supplementary Material PubReader ePub

Purpose
The purpose of this study was to compare ramosetron (RAM), aprepitant (APR), and dexamethasone (DEX) [RAD] with palonosetron (PAL), APR, and DEX [PAD] in controlling highly-emetogenic chemotherapy (HEC)–induced nausea and vomiting.
Materials and Methods
Patients were randomly assigned (1:1) to receive RAD or PAD:RAM (0.3 mg intravenously) or PAL (0.25 mg intravenously) D1, combined with APR (125 mg orally, D1 and 80 mg orally, D2-3) and DEX (12 mg orally or intravenously, D1 and 8 mg orally, D2-4). Patients were stratified by gender, cisplatin-based chemotherapy, and administration schedule. The primary endpoint was overall complete response (CR), defined as no emesis and no rescue regimen during 5 days of HEC. Secondary endpoints were overall complete protection (CP; CR+nausea score < 25 mm) and total control (TC; CR+nausea score < 5 mm). Quality of life was assessed by Functional Living Index Emesis (FLIE) questionnaire on D0 and D6.
Results
A total of 279 patients receiving RAD (n=137) or PAD (n=142) were evaluated. Overall CR rates in RAD and PAD recipients were 81.8% and 79.6% (risk difference [RD], 2.2%; 95% confidence interval [CI], −7.1 to 11.4), respectively. Overall CP and TC rates for RAD and PAD were 56.2% and 58.5% (RD, −2.3%; 95% CI, −13.9 to 9.4) and 47.5% vs. 43.7% (RD, 3.8%; 95% CI, −7.9 to 15.5), respectively. FLIE total score ≥ 108 (no impact on daily life) was comparable between RAD and PAD (73.9% vs. 73.4%, respectively). Adverse events were similar between the two groups.
Conclusion
In all aspects of efficacy, safety and QOL, RAD is non-inferior to PAD for the control of CINV in cancer patients receiving HEC.

Citations

Citations to this article as recorded by

Impact of body weight-based dosing of palonosetron and ondansetron on postoperative nausea and vomiting following laparoscopic sleeve gastrectomy: a randomized, double-blind study
Büşra Burcu, Nadir Adnan Hacım, Ozan Caliskan, Serdar Demirgan, Talar Vartanoglu Aktokmakyan, Serhat Meric, Tomris Duymaz, Onder Karabay, Ali Solmaz
Acta Chirurgica Belgica.2024; 124(1): 41. CrossRef
2023 updated MASCC/ESMO consensus recommendations: prevention of nausea and vomiting following high-emetic-risk antineoplastic agents
Jørn Herrstedt, L Celio, PJ Hesketh, L Zhang, R Navari, A Chan, M Saito, R Chow, M Aapro
Supportive Care in Cancer.2024;[Epub] CrossRef
2023 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting
J. Herrstedt, R. Clark-Snow, C.H. Ruhlmann, A. Molassiotis, I. Olver, B.L. Rapoport, M. Aapro, K. Dennis, P.J. Hesketh, R.M. Navari, L. Schwartzberg, M.L. Affronti, M.A. Garcia-Del-Barrio, A. Chan, L. Celio, R. Chow, M. Fleury, R.J. Gralla, R. Giusti, F.
ESMO Open.2024; 9(2): 102195. CrossRef
Ramosetron 3.0 μg/mL Combining with Dexamethasone (0.05, 0.1, 0.2 mg/mL) in Infusion Solutions: A Physicochemical Stability Study
Baoxia Fang, Lijun Zhao, Shirong Yu, Fuchao Chen
Dose-Response.2024;[Epub] CrossRef
Efficacy and safety of Antiemetic Regimens for Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting: A Systematic Review and Network Meta-Analysis
Marco Filetti, Pasquale Lombardi, Raffaele Giusti, Rosa Falcone, Florian Scotte, Diana Giannarelli, Antonella Carcagnì, Valeria Altamura, Giovanni Scambia, Gennaro Daniele
Cancer Treatment Reviews.2023; : 102512. CrossRef
Effect of Acupuncture on Delayed Emesis for the Patients Who Received High-Emetogenic Chemotherapy with Standard Antiemetic Prophylaxis (KHMC-HO-01): An Open-Label, Randomized Study
Chi Hoon Maeng, Seunghoon Lee, Jae Joon Han, Hong Jun Kim, Dongwoo Nam, Junhee Lee, Sun Kyung Baek, Maria Grazia Ferraro
Evidence-Based Complementary and Alternative Medicine.2022; 2022: 1. CrossRef
Cardioprotective action of aprepitant in a rat model of ischemia-reperfusioninduced myocardial injury: role of PI3K-AkT-GSK-3β-HIF-1α signaling pathway
Mei Qian, Yang Liu
Acta Cirúrgica Brasileira.2022;[Epub] CrossRef
Comparison of the Effectiveness of Palonosetron and Ramosetron in Preventing Postoperative Nausea and Vomiting: Updated Systematic Review and Meta-Analysis with Trial Sequential Analysis
Hyo Jin Kim, EunJin Ahn, Geun Joo Choi, Hyun Kang
Journal of Personalized Medicine.2022; 13(1): 82. CrossRef
Oliceridine is Associated with Reduced Risk of Vomiting and Need for Rescue Antiemetics Compared to Morphine: Exploratory Analysis from Two Phase 3 Randomized Placebo and Active Controlled Trials
Timothy L. Beard, Cathy Michalsky, Keith A. Candiotti, Paul Rider, Linda Wase, Ashraf S. Habib, Mark A. Demitrack, Michael J. Fossler, Eugene R. Viscusi
Pain and Therapy.2021; 10(1): 401. CrossRef
Forsythiae Fructus aqueous extract attenuates cisplatin-induced kaolin consumption (pica) by inhibiting NLRP3 inflammasome activation in rats
Qi Meng, Pingping Bi, Guanglong Zhang, Yaqi Li, Siqi Chen, Ke Nie
Bioscience, Biotechnology, and Biochemistry.2021; 85(9): 2054. CrossRef
Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a network meta-analysis
Vanessa Piechotta, Anne Adams, Madhuri Haque, Benjamin Scheckel, Nina Kreuzberger, Ina Monsef, Karin Jordan, Kathrin Kuhr, Nicole Skoetz
Cochrane Database of Systematic Reviews.2021;[Epub] CrossRef
Duration of dexamethasone administration for the prevention of chemotherapy-induced nausea and vomiting – A systematic review and meta-analysis
Ajay Raghunath, Sahan D. Chandrasekara, Shane N. Anthony, Ben Markman
Critical Reviews in Oncology/Hematology.2020; 152: 103012. CrossRef

10,008 View
199 Download
10 Web of Science
12 Crossref

A Phase II Study to Evaluate the Safety and Efficacy of Pegteograstim in Korean Breast Cancer Patients Receiving Dose-Dense Doxorubicin/Cyclophosphamide: Gun Min Kim, Joo Hoon Kim, Ji Heung Kim, Young Up Cho, Seung Il Kim, Seho Park, Hyung Seok Park, Ji Ye Kim, Joohyuk Sohn; Cancer Res Treat. 2019;51(2):812-818. Published online September 19, 2018; DOI: https://doi.org/10.4143/crt.2018.383

Abstract PDF PubReader ePub

Purpose
Dose-dense chemotherapy (DD-CT) is a preferred (neo)adjuvant regimen in early breast cancer (BC). Although the results of reported randomized trials are conflicting, a recent metaanalysis showed improved overall and disease-free survival with DD-CT compared to conventional schedules. However, no DD-CT safety data for Korean BC patients are available. This phase II study was conducted to evaluate the safety and efficacy of pegteograstim in Korean BC patients receiving DD-CT.
Materials and Methods
Patients with operable (stage I-III), histologically confirmed BC received four cycles of intravenous doxorubicin (60 mg/m2) and cyclophosphamide (600 mg/m2) on day 1 every 2 weeks as neoadjuvant or adjuvant therapy. Pegteograstim (6.0 mg) was administered subcutaneously on day 2 of each cycle. The primary endpoint was the incidence of febrile neutropenia (FN). The secondary endpoints were safety and tolerability.
Results
Of 63 patients, one (1.6%) developed FN during all cycles of DD-CT. Dose delay was observed in four patients (6.3%) and dose reduction in two (3.2%) during DD-CT. Frequent adverse events (AEs) were nausea, alopecia, generalized muscle weakness, myalgia, mucositis, anorexia, dyspepsia, and diarrhea; most AEs were related to chemotherapy. Grade 3-4 AEs were reported in five of 63 patients (7.9%), and all grade 3 and 4 AEs were related to chemotherapy. Adverse drug reactions possibly linked to pegteograstim were abdominal pain, bone pain, myalgia, generalized muscle weakness, and headache in five of 63 patients (7.9%).
Conclusion
Dose-dense AC (doxorubicin/cyclophosphamide) chemotherapywith pegteograstim support is a tolerable and safe regimen in Korean early BC patients.

Citations

Citations to this article as recorded by

Local dose-dense chemotherapy for triple-negative breast cancer via minimally invasive implantation of 3D printed devices
Noehyun Myung, Hyun-Wook Kang
Asian Journal of Pharmaceutical Sciences.2024; 19(1): 100884. CrossRef
Safety and Efficacy of Pegteograstim on Chemotherapy-induced Neutropenia in Children and Adolescents With Solid Tumors
Hee Won Cho, Ji Won Lee, Hee Young Ju, Ju Kyung Hyun, Keon Hee Yoo, Hong Hoe Koo, Kyunga Kim, Ki Woong Sung
Journal of Pediatric Hematology/Oncology.2022; 44(2): e362. CrossRef
Prophylaxis and treatment strategies for optimizing chemotherapy relative dose intensity
Michelle Shayne, R. Donald Harvey, Gary H. Lyman
Expert Review of Anticancer Therapy.2021; 21(10): 1145. CrossRef

8,172 View
267 Download
4 Web of Science
3 Crossref

Feasibility of Charcoal Tattooing of Cytology-Proven Metastatic Axillary Lymph Node at Diagnosis and Sentinel Lymph Node Biopsy after Neoadjuvant Chemotherapy in Breast Cancer Patients: Seho Park, Ja Seung Koo, Gun Min Kim, Joohyuk Sohn, Seung Il Kim, Young Up Cho, Byeong-Woo Park, Vivian Youngjean Park, Jung Hyun Yoon, Hee Jung Moon, Min Jung Kim, Eun-Kyung Kim; Cancer Res Treat. 2018;50(3):801-812. Published online August 17, 2017; DOI: https://doi.org/10.4143/crt.2017.210

Abstract PDF PubReader ePub

Purpose
Sentinel lymph node biopsy (SLNB) can be performed when node-positive disease is converted to node-negative status after neoadjuvant chemotherapy (NCT). Tattooing nodes might improve accuracy but supportive data are limited. This study aimed to investigate the feasibility of charcoal tattooing metastatic axillary lymph node (ALN) at presentation followed by SLNB after NCT in breast cancers.
Materials and Methods
Twenty patientswith cytology-proven node metastases prospectively underwent charcoal tattooing at diagnosis. SLNB using dual tracers and axillary surgery after NCT were then performed. The detection rate of tattooed node and diagnostic performance of SLNB were analyzed.
Results
All patients underwent charcoal tattooingwithout significant morbidity. Sentinel and tattooed nodes could be detected during surgery after NCT. Nodal pathologic complete response was achieved in 10 patients. Overall sensitivity, false-negative rate (FNR), negative predictive value, and accuracy of hot/blue SLNB were 80.0%, 20.0%, 83.3%, and 90.0%, respectively. Retrieving more nodes and favorable nodal response were associated with improved performance. The best accuracy was observed when excised tattooed node was calculated together (FNR, 0.0%). Cold/non-blue tattooed nodes of five patients were removed during non-sentinel axillary surgery but clinicopathological parameters did not differ compared to patients with hot/blue tattooed node detected during SLNB, suggesting the importance of the tattooing procedure itself to improve performance.
Conclusion
Charcoal tattooing of cytology-confirmed metastatic ALN at presentation is technically feasible and does not limit SLNB after NCT. The tattooing procedure without additional preoperative localization is advantageous for improving the diagnostic performance of SLNB in this setting.

Citations

Citations to this article as recorded by

Indocyanine Green Fluorescence Plus Blue Dye for Sentinel Lymph Node Biopsy in Patients Undergoing Neoadjuvant Chemotherapy for Breast Cancer: A Multicenter, Prospective Cohort Study
Miao Liu, Yang Yang, Bin Hua, Rui Feng, Tianyu Xu, Mengyuan Wang, Xiaowei Qi, Yingming Cao, Bo Zhou, Fuzhong Tong, Peng Liu, Hongjun Liu, Lin Cheng, Houpu Yang, Fei Xie, Siyuan Wang, Chaobin Wang, Yuan Peng, Danhua Shen, Lei Chen, Jun Jiang, Shu Wang
Thoracic Cancer.2025;[Epub] CrossRef
The efficacy and oncological safety of minimally invasive axillary procedures in patients with node-positive breast cancer receiving neoadjuvant chemotherapy: a network meta-regression and trial sequential analysis
James Lucocq, Hassan Baig, Esther McNeill, J Michael Dixon
European Journal of Surgical Oncology.2025; : 109689. CrossRef
Radiographic identification of a positive clipped axillary lymph node in a mastectomy specimen following neoadjuvant chemotherapy
Andrew Seto, Cynthia Lin, Samantha Norden, Jamie Stratton, Moira O'Riordan, Helen Pass
Radiology Case Reports.2024; 19(1): 435. CrossRef
Peut-on surseoir au curage axillaire en cas de carcinome mammaire invasif avec envahissement ganglionnaire ?
Susie Brousse, Clémentine Lafond, Martin Schmitt, Sophie Guillermet, Sébastien Molière, Carole Mathelin
Gynécologie Obstétrique Fertilité & Sénologie .2024; 52(3): 132. CrossRef
The Role of Level III Dissection in Locally Advanced Breast Cancer following Neoadjuvant Chemotherapy—A Prospective Study
Rexeena V. Bhargavan, Nisha Prasannan, K.M. Jagathnath Krishna, Paul Augustine, Kurian Cherian
South Asian Journal of Cancer.2024; 13(03): 170. CrossRef
Melanin-Based Nanoparticles for Lymph Node Tattooing: Experimental, Histopathological and Ultrastructural Study
Marta Baselga, Antonio Güemes, Cristina Yus, Teresa Alejo, Víctor Sebastián, Dolores Arribas, Gracia Mendoza, Eva Monleón, Manuel Arruebo
Nanomaterials.2024; 14(13): 1149. CrossRef
Utility of a breast biopsy clip and a point marker system in tailored axillary surgery for patients with breast cancer after neoadjuvant chemotherapy
Yuka Endo, Haruru Kotani, Nobuko Tamura, Kiyo Tanaka, Chiho Kudo, Masataka Sawaki, Masaya Hattori, Akiyo Yoshimura, Ayumi Kataoka, Kazuki Nozawa, Yuri Ozaki, Ayaka Isogai, Rie Komaki, Akira Nakakami, Nari Kureyama, Maho Kusudo, Waki Hosoda, Hidetaka Kawab
Breast Cancer.2024; 31(6): 1130. CrossRef
Oncological outcomes of selective axillary dissection with 4% carbon marking
LUCAS ROSKAMP BUDEL, CLEVERTON CÉSAR SPAUTZ, MARIA HELENA LOUVEIRA, TERESA CRISTINA SANTOS CAVALCANTI, ALESSANDRA CORDEIRO FORNAZARI, PLINIO GASPERIN JUNIOR, LEONARDO NISSEN, VINICIUS MILANI BUDEL
Revista do Colégio Brasileiro de Cirurgiões.2024;[Epub] CrossRef
Desfechos oncológicos da dissecção axilar seletiva utilizando carvão a 4% como marcador
LUCAS ROSKAMP BUDEL, CLEVERTON CÉSAR SPAUTZ, MARIA HELENA LOUVEIRA, TERESA CRISTINA SANTOS CAVALCANTI, ALESSANDRA CORDEIRO FORNAZARI, PLINIO GASPERIN JUNIOR, LEONARDO NISSEN, VINICIUS MILANI BUDEL
Revista do Colégio Brasileiro de Cirurgiões.2024;[Epub] CrossRef
Preclinical evaluation of polymer encapsulated carbon-based nano and microparticles for sentinel lymph node tattooing
Marta Baselga, Antonio Güemes, Manuel Arruebo, Cristina Yus, Teresa Alejo, Víctor Sebastián, Gema Martínez, Dolores Arribas, Gracia Mendoza, Concepción Junquera, Eva Monleón
Scientific Reports.2024;[Epub] CrossRef
Biopsia del ganglio centinela y disección axilar dirigida en mujeres con cáncer de mama y axila positiva en el momento del diagnóstico: caminando hacia el futuro
Paula Moral Rubio, Silvia Delgado García, Hortensia Ballester Galiana, Jose Ponce Lorenzo, Tina Martín Bayón, Gloria Peiró
Revista de Senología y Patología Mamaria.2023; 36(1): 100402. CrossRef
Estadificación ganglionar tras terapia sistémica primaria en mujeres con cáncer de mama y afectación ganglionar al diagnóstico
Eva Acea-Figueira, Alejandra García-Novoa, Carlota Díaz Carballada, Alberto Bouzón Alejandro, Carmen Conde, Paz Santiago Freijanes, Joaquín Mosquera Oses, Benigno Acea-Nebril
Cirugía Española.2023; 101(6): 417. CrossRef
Lymph node staging after primary systemic therapy in women with breast cancer and lymph node involvement at diagnosis
Eva Acea-Figueira, Alejandra García-Novoa, Carlota Díaz Carballada, Alberto Bouzón Alejandro, Carmen Conde, Paz Santiago Freijanes, Joaquín Mosquera Oses, Benigno Acea-Nebril
Cirugía Española (English Edition).2023; 101(6): 417. CrossRef
Carbon tattooing of axillary lymph nodes in breast cancer patients before neoadjuvant chemotherapy: A retrospective analysis
Mauro Porpiglia, Fulvio Borella, Pierluigi Chieppa, Carola Brino, Ada Ala, Vincenzo Marra, Isabella Castellano, Chiara Benedetto
Tumori Journal.2023; 109(3): 301. CrossRef
Concomitant Use of Biopsy Clips and Wire Localization in Invasive Breast Cancer is Associated With Successful Clip Retrieval
Jennifer H. Chen, Joe K. Canner, Kelly Myers, Melissa Camp
Clinical Breast Cancer.2023; 23(3): e163. CrossRef
Carbon nanoparticles localized clipped node dissection combined with sentinel lymph node biopsy with indocyanine green and methylene blue after neoadjuvant therapy in node positive breast cancer in China: initial results of a prospective study
Xin Yang, Yao Li, Xiao-tian Ren, Lei Fan, Bin Hua
World Journal of Surgical Oncology.2023;[Epub] CrossRef
Outcomes of Sentinel Node Biopsy for Women with Breast Cancer After Neoadjuvant Therapy: Systematic Review and Meta-Analysis of Real-World Data
Shi-Qian Lin, Nguyen-Phong Vo, Yu-Chun Yen, Ka-Wai Tam
Annals of Surgical Oncology.2022; 29(5): 3038. CrossRef
Nanoparticle-assisted axillary staging: an alternative approach after neoadjuvant chemotherapy in patients with pretreatment node-positive breast cancers
Jiqiao Yang, Tao He, Yunhao Wu, Zhoukai Fu, Qing Lv, Shan Lu, Xiaodong Wang, Hongjiang Li, Jing Wang, Jie Chen
Breast Cancer Research and Treatment.2022; 192(3): 573. CrossRef
Axillary Management: How Has Neoadjuvant Chemotherapy Changed Our Surgical Approach?
Mara A. Piltin, Judy C. Boughey
Current Breast Cancer Reports.2022; 14(1): 1. CrossRef
Gezielte Entfernung axillärer Lymphknoten nach Kohlenstoffmarkierung bei Patientinnen mit primär systemisch behandeltem Mammakarzinom
Steffi Hartmann, Angrit Stachs, Thorsten Kühn, Jana de Boniface, Maggie Banys-Paluchowski, Toralf Reimer
Senologie - Zeitschrift für Mammadiagnostik und -therapie.2022; 19(01): 49. CrossRef
Gezielte Entfernung axillärer Lymphknoten nach Kohlenstoffmarkierung bei Patientinnen mit primär systemisch behandeltem Mammakarzinom
Steffi Hartmann, Angrit Stachs, Thorsten Kühn, Jana de Boniface, Maggie Banys-Paluchowski, Toralf Reimer
TumorDiagnostik & Therapie.2022; 43(03): 197. CrossRef
False-negative rate in the extended prospective TATTOO trial evaluating targeted axillary dissection by carbon tattooing in clinically node-positive breast cancer patients receiving neoadjuvant systemic therapy
Jana de Boniface, Jan Frisell, Thorsten Kühn, Ingrid Wiklander-Bråkenhielm, Karin Dembrower, Per Nyman, Athanasios Zouzos, Bernd Gerber, Toralf Reimer, Steffi Hartmann
Breast Cancer Research and Treatment.2022; 193(3): 589. CrossRef
Diagnostic accuracy of de‐escalated surgical procedure in axilla for node‐positive breast cancer patients treated with neoadjuvant systemic therapy: A systematic review and meta‐analysis
Yu‐xin Song, Zheng Xu, Ming‐xing Liang, Zhen Liu, Jun‐chen Hou, Xiu Chen, Di Xu, Yin‐jiao Fei, Jin‐hai Tang
Cancer Medicine.2022; 11(22): 4085. CrossRef
Multidisciplinary considerations in the management of breast cancer patients receiving neoadjuvant chemotherapy
Faina Nakhlis, Leah Portnow, Eva Gombos, Ayse Ece Cali Daylan, Jose Pablo Leone, Olga Kantor, Edward T. Richardson, Alice Ho, Samantha Armstrong Dunn, Nisha Ohri
Current Problems in Surgery.2022; 59(9): 101191. CrossRef
Combining Wire Localization of Clipped Nodes with Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy in Node-Positive Breast Cancer: Preliminary Results from a Prospective Study
Alejandra García-Novoa, Benigno Acea-Nebril, Carlota Díaz Carballada, Alberto Bouzón Alejandro, Carmen Conde, Carmen Cereijo Garea, José Ramón Varela, Paz Santiago Freijanes, Silvia Antolín Novoa, Lourdes Calvo Martínez, Inma Díaz, Sofia Rodríguez Martíne
Annals of Surgical Oncology.2021; 28(2): 958. CrossRef
A multicentre prospective feasibility study of carbon dye tattooing of biopsied axillary node and surgical localisation in breast cancer patients
Amit Goyal, Shama Puri, Andrea Marshall, Kalliope Valassiadou, Moin M. Hoosein, Amtul R. Carmichael, Gabriella Erdelyi, Nisha Sharma, Janet Dunn, Joanne York
Breast Cancer Research and Treatment.2021; 185(2): 433. CrossRef
Carbon tattooing for targeted lymph node biopsy after primary systemic therapy in breast cancer: prospective multicentre TATTOO trial
S Hartmann, T Kühn, J de Boniface, A Stachs, A Winckelmann, J Frisell, I Wiklander-Bråkenhielm, J Stubert, B Gerber, T Reimer
British Journal of Surgery.2021; 108(3): 302. CrossRef
Different strategies in marking axillary lymph nodes in breast cancer patients undergoing neoadjuvant medical treatment: a systematic review
Vivian Man, Ava Kwong
Breast Cancer Research and Treatment.2021; 186(3): 607. CrossRef
Sentinel lymph node BIOPSY after neoadjuvant therapy in breast cancer patients with lymph node involvement at diagnosis. Could wire localization of clipped node improve our results?
Marina Alarcón, Elvira Buch, Ana Julve, Marta Hernandorena, Marcos Tajahuerce, Héctor Rodríguez, Begoña Bermejo, Judith Ramírez, Octavio Burgués, Sandra Díaz, Gara M. Alcalá, Joaquín Ortega
The Surgeon.2021; 19(6): 344. CrossRef
The Evolving Role of Marked Lymph Node Biopsy (MLNB) and Targeted Axillary Dissection (TAD) after Neoadjuvant Chemotherapy (NACT) for Node-Positive Breast Cancer: Systematic Review and Pooled Analysis
Parinita K. Swarnkar, Salim Tayeh, Michael J. Michell, Kefah Mokbel
Cancers.2021; 13(7): 1539. CrossRef
New horizons in imaging and surgical assessment of breast cancer lymph node metastasis
Firouzeh Arjmandi, Ann Mootz, Deborah Farr, Sangeetha Reddy, Basak Dogan
Breast Cancer Research and Treatment.2021; 187(2): 311. CrossRef
Assessment of axillary node status by ultrasound after neoadjuvant chemotherapy in patients with clinically node-positive breast cancer according to breast cancer subtype
Yurina Maeshima, Takehiko Sakai, Akiko Ogiya, Yoko Takahashi, Yumi Miyagi, Yumi Kokubu, Tomo Osako, Yoshinori Ito, Shunji Takahashi, Shinji Ohno, Takayuki Ueno
Scientific Reports.2021;[Epub] CrossRef
Targeted axillary biopsy and sentinel lymph node biopsy for axillary restaging after neoadjuvant chemotherapy
Gunay Gurleyik, Sibel Aydin Aksu, Fügen Aker, Kubra Kaytaz Tekyol, Eda Tanrikulu, Emin Gurleyik
Annals of Surgical Treatment and Research.2021; 100(6): 305. CrossRef
Options to Determine Pathological Response of Axillary Lymph Node Metastasis after Neoadjuvant Chemotherapy in Advanced Breast Cancer
Vijayashree Murthy, Jessica Young, Yoshihisa Tokumaru, Marie Quinn, Stephen B. Edge, Kazuaki Takabe
Cancers.2021; 13(16): 4167. CrossRef
Influence of Imaging Features and Technique on US-guided Tattoo Ink Marking of Axillary Lymph Nodes Removed at Sentinel Lymph Node Biopsy in Women With Breast Cancer
Marlen Pajcini, Irene Wapnir, Jacqueline Tsai, Joanne Edquilang, Wendy DeMartini, Debra Ikeda
Journal of Breast Imaging.2021; 3(5): 583. CrossRef
Targeted Removal of Axillary Lymph Nodes After Carbon Marking in Patients with Breast Cancer Treated with Primary Chemotherapy
Steffi Hartmann, Angrit Stachs, Thorsten Kühn, Jana de Boniface, Maggie Banys-Paluchowski, Toralf Reimer
Geburtshilfe und Frauenheilkunde.2021; 81(10): 1121. CrossRef
Axillary Imaging Following a New Invasive Breast Cancer Diagnosis—A Radiologist’s Dilemma
Vandana Dialani, Basak Dogan, Katerina Dodelzon, Brian N Dontchos, Neha Modi, Lars Grimm
Journal of Breast Imaging.2021; 3(6): 645. CrossRef
Selective Extirpation of Tattooed Lymph Node in Combination with Sentinel Lymph Node Biopsy in the Management of Node-Positive Breast Cancer Patients after Neoadjuvant Systemic Therapy
Lukas Dostalek, Andrej Cerny, Petra Saskova, David Pavlista
Breast Care.2021; 16(6): 623. CrossRef
False Negativity of Targeted Axillary Dissection in Breast Cancer
George Kirkilesis, Anastasia Constantinidou, Michalis Kontos
Breast Care.2021; 16(5): 532. CrossRef
Synchronous early‑stage breast cancer and axillary follicular lymphoma diagnosed by core needle biopsy: A case report
Ryotaro Eto, Rikiya Nakamura, Naohito Yamamoto, Toshiko Miyaki, Shoko Hayama, Itaru Sonoda, Makiko Itami, Hideki Tsujimura, Hideyuki Hashimoto, Masayuki Otsuka
Molecular and Clinical Oncology.2021;[Epub] CrossRef
Breast and axillary surgery in malignant breast disease: a review focused on literature of 2018 and 2019
Nina Ditsch, Isabel T. Rubio, Maria L. Gasparri, Jana de Boniface, Thorsten Kuehn
Current Opinion in Obstetrics & Gynecology.2020; 32(1): 91. CrossRef
Targeted axillary dissection after neoadjuvant systemic therapy in patients with node‐positive breast cancer
Kavitha Kanesalingam, Nina Sriram, Ghaith Heilat, E ‐Ern Ng, Farid Meybodi, Elisabeth Elder, Meagan Brennan, James French
ANZ Journal of Surgery.2020; 90(3): 332. CrossRef
Initial results of a novel technique of clipped node localization in breast cancer patients postneoadjuvant chemotherapy: Skin Mark clipped Axillary nodes Removal Technique (SMART trial)
Geok Hoon Lim, Sze Yiun Teo, Mihir Gudi, Ruey Pyng Ng, Jinnie Pang, Yia Swam Tan, Yien Sien Lee, John C. Allen, Lester Chee Hao Leong
Cancer Medicine.2020; 9(6): 1978. CrossRef
Targeted axillary dissection of carbon‐tattooed metastatic lymph nodes in combination with post–neo‐adjuvant sentinel lymph node biopsy using 1% methylene blue in breast cancer patients
Emad Khallaf, Rasha Wessam, Mohamed Abdoon
The Breast Journal.2020; 26(5): 1061. CrossRef
Marking axillary nodes with 4% carbon microparticle suspension before neoadjuvant chemotherapy improves sentinel node identification rate and axillary staging
Cleverton Cesar Spautz, Eduardo Schunemann Junior, Lucas Roskamp Budel, Tereza Cristina Santos Cavalcanti, Maria Helena Louveira, Plinio Gasperin Junior, Leonardo Paese Nissen, Bernardo Passos Sobreiro, Maíra Teixeira Dória, Cicero Andrade Urban, Vinicius
Journal of Surgical Oncology.2020; 122(2): 164. CrossRef
Targeted Axillary Dissection for Patients Who Convert to Clinically Node Negative After Neoadjuvant Chemotherapy for Node-Positive Breast Cancer
Kandice Ludwig, Amanda L. Kong
Current Breast Cancer Reports.2020; 12(4): 391. CrossRef
Clinical Practice Status of Sentinel Lymph Node Biopsy for Early-Stage Breast Cancer Patients in China: A Multicenter Study

Juliang Zhang, Ting Wang, Changjiao Yan, Meiling Huang, Zhimin Fan, Rui Ling
Clinical Epidemiology.2020; Volume 12: 917. CrossRef
Feasibility of preoperative tattooing of percutaneously biopsied axillary lymph node: an experimental pilot study
Abida K. Sattar, Basim Ali, Imrana Masroor, Shaista Afzal, Mohammad Usman Tariq, Romana Idrees, Maseeh Uzzaman, Wardah Khalid
Pilot and Feasibility Studies.2020;[Epub] CrossRef
Effectiveness of preoperative ultrasound-guided charcoal tattooing for localization of metastatic melanoma
Ji Hyun Lee, Hyun Su Kim, Young Cheol Yoon, Min Je Kim, Min Jae Cha, Jung-Han Kim
Ultrasonography.2020; 39(4): 376. CrossRef
To Evaluate the Accuracy of Axillary Staging Using Ultrasound and Ultrasound-Guided Fine-Needle Aspiration Cytology (USG-FNAC) in Early Breast Cancer Patients—a Prospective Study
Rashpal Singh, S. V. S. Deo, Ekta Dhamija, Sandeep Mathur, Sanjay Thulkar
Indian Journal of Surgical Oncology.2020; 11(4): 726. CrossRef
Leveraging Neoadjuvant Chemotherapy to Minimize the Burden of Axillary Surgery: a Review of Current Strategies and Surgical Techniques
Alison Laws, Michelle C. Specht
Current Breast Cancer Reports.2020; 12(4): 317. CrossRef
Diagnostic Accuracy of Different Surgical Procedures for Axillary Staging After Neoadjuvant Systemic Therapy in Node-positive Breast Cancer
Janine M. Simons, Thiemo J. A. van Nijnatten, Carmen C. van der Pol, Ernest J. T. Luiten, Linetta B. Koppert, Marjolein L. Smidt
Annals of Surgery.2019; 269(3): 432. CrossRef
Axillary Lymph Node Tattooing and Targeted Axillary Dissection in Breast Cancer Patients Who Presented as cN+ Before Neoadjuvant Chemotherapy and Became cN0 After Treatment
Ioannis Natsiopoulos, Stavros Intzes, Triantafyllos Liappis, Konstantinos Zarampoukas, Thomas Zarampoukas, Vasiliki Zacharopoulou, Konstantinos Papazisis
Clinical Breast Cancer.2019; 19(3): 208. CrossRef
Pretreatment Tattoo Marking of Suspicious Axillary Lymph Nodes: Reliability and Correlation with Sentinel Lymph Node
Rupa Patel, Wendy MacKerricher, Jacqueline Tsai, Nicole Choy, Jafi Lipson, Debra Ikeda, Sunita Pal, Wendy De Martini, Kimberly H. Allison, Irene L. Wapnir
Annals of Surgical Oncology.2019; 26(8): 2452. CrossRef
Node positive breast cancer: Concordance between baseline PET/CT and sentinel node assessment after neoadjuvant therapy
Oscar Leopoldo Christin, Jonathan Kuten, Einat Even-Sapir, Joseph Klausner, Tehillah S. Menes
Surgical Oncology.2019; 30: 1. CrossRef
Sentinel Node Lymph Node Surgery After Neoadjuvant Therapy: Principles and Techniques
Jennifer M. Racz, Abigail S. Caudle
Annals of Surgical Oncology.2019; 26(10): 3040. CrossRef
Excision of both pretreatment marked positive nodes and sentinel nodes improves axillary staging after neoadjuvant systemic therapy in breast cancer
J M Simons, M L M A van Pelt, A W K S Marinelli, M E Straver, A M Zeillemaker, L M Pereira Arias-Bouda, T J A van Nijnatten, L B Koppert, K K Hunt, M L Smidt, E J T Luiten, C C van der Pol
British Journal of Surgery.2019; 106(12): 1632. CrossRef
Ultrasound-guided dual-localization for axillary nodes before and after neoadjuvant chemotherapy with clip and activated charcoal in breast cancer patients: a feasibility study
Won Hwa Kim, Hye Jung Kim, See Hyung Kim, Jin Hyang Jung, Ho Yong Park, Jeeyeon Lee, Wan Wook Kim, Ji Young Park, Yee Soo Chae, Soo Jung Lee
BMC Cancer.2019;[Epub] CrossRef
Conservative Management of Positive Axilla After Neoadjuvant Systemic Therapy—The Need for, and Review of, Techniques Used for Lymph Node Localization
Matthew Green, Foteini Neamonitou, Raghavan Vidya
Clinical Breast Cancer.2018; 18(5): e739. CrossRef
Surgical Standards for Management of the Axilla in Breast Cancer Clinical Trials with Pathological Complete Response Endpoint
Judy C. Boughey, Michael D. Alvarado, Rachael B. Lancaster, W. Fraser Symmans, Rita Mukhtar, Jasmine M. Wong, Cheryl A. Ewing, David A. Potter, Todd M. Tuttle, Tina J. Hieken, Jodi M. Carter, James W. Jakub, Henry G. Kaplan, Claire L. Buchanan, Nora T. Ja
npj Breast Cancer.2018;[Epub] CrossRef

12,642 View
360 Download
59 Web of Science
60 Crossref

Case Report

A Case of Combined Hepatocellular-Cholangiocarcinoma with Favorable Response to Systemic Chemotherapy: Gun Min Kim, Hei-Cheul Jeung, Dokyung Kim, Joo Hoon Kim, Sang Hyun Yoon, Eun Suk Jung, Sang Joon Shin; Cancer Res Treat. 2010;42(4):235-238. Published online December 31, 2010; DOI: https://doi.org/10.4143/crt.2010.42.4.235

Abstract PDF PubReader ePub

Combined hepatocellular-cholangiocarcinoma (cHCC-CC) is a rare form of primary liver cancer composed of cells with histopathologic features of both hepatocellular carcinoma (HCC) and cholangiocarcinoma (CC). Because of its low incidence, the information on clinical outcomes of cHCC-CC is very limited and there are no published reports describing non-surgical treatment options for cHCC-CC. We report a case of cHCC-CC exhibiting a favorable response to systemic chemotherapy with doxorubicin and cisplatin. A 62-year-old man who recurred after a right lobectomy for cHCC-CC received sorafenib for palliative systemic therapy, but follow up imaging studies showed disease progression. He received 2nd line chemotherapy with doxorubicin at 60 mg/m² together with cisplatin at 70 mg/m². After 2 cycles of chemotherapy, a computed tomography scan of the chest showed markedly decreased size and number of the multiple lung metastases. After completing 8 cycles of 2nd line therapy, we changed the regimen to a fluorouracil (5-FU) mono therapy because of the toxicities associated with doxorubicin and cisplatin. To date, the patient has completed his 15th cycle of 5-FU mono therapy with the disease status remaining stable during 18 months of follow-up.

Citations

Citations to this article as recorded by

Combined Hepatocellular-Cholangiocarcinoma: Biology, Diagnosis, and Management
Liangtao Ye, Julia S. Schneider, Najib Ben Khaled, Peter Schirmacher, Carolin Seifert, Lea Frey, Yulong He, Andreas Geier, Enrico N. De Toni, Changhua Zhang, Florian P. Reiter
Liver Cancer.2024; 13(1): 6. CrossRef
A New Scoring Method for Personalized Prognostic Prediction in Patients with Combined Hepatocellular and Cholangiocarcinoma After Surgery
Feng Zhang, Keshu Hu, Bei Tang, Mengxin Tian, Shenxin Lu, Jia Yuan, Miao Li, Rongxin Chen, Zhenggang Ren, Yinghong Shi, Xin Yin
Journal of Gastrointestinal Surgery.2021; 25(4): 971. CrossRef
Treatment of Combined Hepatocellular and Cholangiocarcinoma
Simona Leoni, Vito Sansone, Stefania De Lorenzo, Luca Ielasi, Francesco Tovoli, Matteo Renzulli, Rita Golfieri, Daniele Spinelli, Fabio Piscaglia
Cancers.2020; 12(4): 794. CrossRef
Therapy of Primary Liver Cancer
Mei Feng, Yisheng Pan, Ruirui Kong, Shaokun Shu
The Innovation.2020; 1(2): 100032. CrossRef
Combined hepatocellular-cholangiocarcinoma successfully treated with sorafenib: case report and review of the literature
Yuka Futsukaichi, Kazuto Tajiri, Saito Kobayashi, Kohei Nagata, Satoshi Yasumura, Terumi Takahara, Masami Minemura, Ichiro Yasuda
Clinical Journal of Gastroenterology.2019; 12(2): 128. CrossRef
Clinical and pathological features of combined hepatocellular–cholangiocarcinoma compared with other liver cancers
Kazuki Wakizaka, Hideki Yokoo, Toshiya Kamiyama, Masafumi Ohira, Koichi Kato, Yuki Fujii, Ko Sugiyama, Naoki Okada, Takanori Ohata, Akihisa Nagatsu, Shingo Shimada, Tatsuya Orimo, Hirofumi Kamachi, Akinobu Taketomi
Journal of Gastroenterology and Hepatology.2019; 34(6): 1074. CrossRef
Locoregional Therapy of Hepatocellular-Cholangiocarcinoma versus Hepatocellular Carcinoma: A Propensity Score–Matched Study
Yu-Hui Huang, Benjamin V. Park, Yi-Fan Chen, Ron C. Gaba, Grace Guzman, R. Peter Lokken
Journal of Vascular and Interventional Radiology.2019; 30(9): 1317. CrossRef
Multicenter retrospective analysis of systemic chemotherapy for unresectable combined hepatocellular and cholangiocarcinoma
Satoshi Kobayashi, Takeshi Terashima, Satoshi Shiba, Yukio Yoshida, Ikuhiro Yamada, Shouta Iwadou, Shigeru Horiguchi, Hideaki Takahashi, Eiichiro Suzuki, Michihisa Moriguchi, Kunihiro Tsuji, Taiga Otsuka, Akinori Asagi, Yasushi Kojima, Ryoji Takada, Chigu
Cancer Science.2018; 109(8): 2549. CrossRef
Yttrium-90 Radioembolization for Unresectable Combined Hepatocellular-Cholangiocarcinoma
Lauren S. Chan, Daniel Y. Sze, George A. Poultsides, John D. Louie, Mohammed A. Abdelrazek Mohammed, David S. Wang
CardioVascular and Interventional Radiology.2017; 40(9): 1383. CrossRef
A Case of Curative Resection of Advanced Combined Hepatocellular-cholangiocarcinoma after Neoadjuvant Chemotherapy
Jee Eun Choi, Kyung Hee Kim, Seon A Kim, Jung Hwan Lee, Sang Myung Woo, Sang-Jae Park, Eun Kyung Hong, Woo Jin Lee
Korean Journal of Pancreas and Biliary Tract.2016; 21(2): 101. CrossRef
Combined hepatocellular cholangiocarcinoma: Controversies to be addressed
An-Qiang Wang
World Journal of Gastroenterology.2016; 22(18): 4459. CrossRef
Biphenotypic Primary Liver Carcinomas: Assessing Outcomes of Hepatic Directed Therapy
Kathryn Fowler, Nael E. Saad, Elizabeth Brunt, M. B. Majella Doyle, Manik Amin, Neeta Vachharajani, Benjamin Tan, William C. Chapman
Annals of Surgical Oncology.2015; 22(13): 4130. CrossRef
Combined hepatocellular-cholangiocarcinoma (cHCC-CC): a distinct entity
Kate O’Connor, Joanna C. Walsh, David F. Schaeffer
Annals of Hepatology.2014; 13(3): 317. CrossRef
Transplantation versus resection for patients with combined hepatocellular carcinoma–cholangiocarcinoma
Ryan T. Groeschl, Kiran K. Turaga, T. Clark Gamblin
Journal of Surgical Oncology.2013; 107(6): 608. CrossRef

11,294 View
83 Download
14 Crossref

Original Article

Clinicopathologic Features of Metachronous or Synchronous Gastric Cancer Patients with Three or More Primary Sites: Joo Hoon Kim, Sun Young Rha, Chan Kim, Gun Min Kim, Sang Hyun Yoon, Ki Hyang Kim, Min Jae Kim, Joong Bae Ahn, Hyun Cheol Chung, Jae Kyung Roh, Hyo Song Kim; Cancer Res Treat. 2010;42(4):217-224. Published online December 31, 2010; DOI: https://doi.org/10.4143/crt.2010.42.4.217

Abstract PDF PubReader ePub

Purpose

We investigated the clinicopathologic information of patients with gastric cancer with multiple primary cancers (GC-MPC) of three or more sites.

Materials and Methods

Between 1995 and 2009, 105,908 patients were diagnosed with malignancy at Severance Hospital, Yonsei University Health System. Of these, 113 (0.1%) patients with MPC of three or more sites were registered, and 41 (36.3%) of these were GC-MPC. We retrospectively reviewed the clinical data and overall survival using the medical records of these 41 GC-MPC patients. We defined synchronous cancers as those occurring within 6 months of the first primary cancer, while metachronous cancers were defined as those occurring more than 6 months later.

Results

Patients with metachronous GC-MPC were more likely to be female (p=0.003) and young than patients with synchronous GC-MPC (p=0.013). The most common cancer sites for metachronous GC-MPC patients were the colorectum, thyroid, lung, kidney and breast, while those for synchronous GC-MPC were the head and neck, esophagus, lung, and kidney. Metachronous GC-MPC demonstrated significantly better overall survival than synchronous GC-MPC, with median overall survival durations of 4.7 and 14.8 years, respectively, and 10-year overall survival rates of 48.2% and 80.7%, respectively (p<0.001).

Conclusion

Multiplicity of primary malignancies itself does not seem to indicate a poor prognosis. The early detection of additional primary malignancies will enable proper management with curative intent.

Citations

Citations to this article as recorded by

Metachronous or Synchronous Presentation of Acute Myeloid Leukemia and Lung Cancer: A Single Center Experience
Başak Ünver Koluman, Atike Gökçen Demiray, Gulsum Akgun Cagliyan, Sibel Hacıoğlu, Nil Güler, Taner Durak, Yeliz Karakaya, Ferda Bir
Akdeniz Medical Journal.2024;[Epub] CrossRef
A Disguising Fast-Growing Metachronous Melanoma and COVID-19
Alina Avram, Lucian G Scurtu, Mariana Costache, Olga Simionescu
Cureus.2023;[Epub] CrossRef
Solitary solutions to a metastasis model represented by two systems of coupled Riccati equations
I. Timofejeva, T. Telksnys, Z. Navickas, R. Marcinkevicius, R. Mickevicius, M. Ragulskis
Journal of King Saud University - Science.2023; 35(5): 102682. CrossRef
Triple synchronous malignancies of the stomach, bladder and thyroid in a previously treated prostate cancer patient: A Case Report
Oliver Oey, Siaw Sze Tiong, Sze Ling Wong, Suresh Navadgi, Yasir Khan
Folia Medica.2023; 65(4): 693. CrossRef
Features of synchronous and metachronous dual primary gastric and colorectal cancer
Yi-Jia Lin, Hua-Xian Chen, Feng-Xiang Zhang, Xian-Sheng Hu, Hai-Juan Huang, Jian-Hua Lu, Ye-Zi Cheng, Jun-Sheng Peng, Lei Lian
World Journal of Gastrointestinal Oncology.2023; 15(11): 1864. CrossRef
Definitions and treatment of oligometastatic oesophagogastric cancer according to multidisciplinary tumour boards in Europe
Tiuri E. Kroese, Richard van Hillegersberg, Sebastian Schoppmann, Pieter R.A.J. Deseyne, Philippe Nafteux, Radka Obermannova, Marianne Nordsmark, Per Pfeiffer, Maria A. Hawkins, Elizabeth Smyth, Sheraz Markar, George B. Hanna, Edward Cheong, Asif Chaudry,
European Journal of Cancer.2022; 164: 18. CrossRef
Stereotactic radiotherapy or metastasectomy for oligometastatic esophagogastric cancer: A nationwide population-based cohort study
Tiuri E. Kroese, Nikita K.N. Jorritsma, Hanneke W.M. van Laarhoven, Rob H.A. Verhoeven, Stella Mook, Nadia Haj Mohammad, Jelle P. Ruurda, Peter S.N. van Rossum, Richard van Hillegersberg
Clinical and Translational Radiation Oncology.2022; 37: 109. CrossRef
Simultaneous triple primary malignancies, including bladder cancer, lymphoma, and lung cancer, in an elderly male: A case report
Risheng Huang, Zhijia Li, Shanshan Weng, Shenghao Wu
Open Life Sciences.2022; 17(1): 1263. CrossRef
A Case Report of Mesothelioma Response to Endocrine Therapy in Synchronous Breast Cancer and Pleural Epithelioid Mesothelioma: A Double Exemestane Effect
Marta Pina, Rute Fernandes, Diogo Fonseca, Cristina Oliveira, Ana Rodrigues
Cureus.2022;[Epub] CrossRef
Management of patients with synchronous head-and-neck and lung cancers
Nicolas Paleiron, Radj Gervais, Gaelle Rousseau-Bussac, Laurence Bigay Game, Anne Marie Chiappa, Regine Lamy, Florian Guisier, Hervé Le Caer, Gilles Robinet, Acya Bizieux, Christos Chouaïd
Journal of Cancer Research and Therapeutics.2022; 18(Suppl 2): S160. CrossRef
Multiple primary malignancies involving lung cancer: a single-center experience
Luigi Ventura, Paolo Carbognani, Letizia Gnetti, Maurizio Rossi, Marcello Tiseo, Enrico Maria Silini, Nicola Sverzellati, Mario Silva, Marcello Succi, Cesare Braggio, Sara Cattadori, Giovanni Bocchialini, Valeria Balestra, Michele Rusca, Luca Ampollini
Tumori Journal.2021; 107(3): 196. CrossRef
A Case Series of Multiple Primary Malignancies Among Patients With Advanced Melanoma
Matthew I Ebia, Stephen Capone, Charité Ricker, Jacob S Thomas, Varsha Tulpule, Irene Kang, Anishka D'Souza, David R Freyer, Kimberly Miller, Gino K In
Cureus.2021;[Epub] CrossRef
A Rare Case of Synchronous Esophageal and Pancreatic Malignancy
Ali Khalifa, Arkady Broder
Cureus.2021;[Epub] CrossRef
Efficacy and Safety of Local Radiotherapy to All Oligometastatic Sites in Elderly Patients with Metachronous Oligometastatic Cancers After Initial Treatment for the Primary Tumor
Xiaolong Hu, Hongqi Li, Xiaoli Kang, Xuan Wang, Haifeng Pang, Chen Liu, Jianchun Zhang, Yingjie Wang
Cancer Management and Research.2021; Volume 13: 9247. CrossRef
Synergistic Effect of Lymphatic Invasion and Venous Invasion on the Risk of Lymph Node Metastasis in Patients with Non-Curative Endoscopic Resection of Early Gastric Cancer
Hye Jin Kang, Hyunsoo Chung, Sang Gyun Kim, Jung Kim, Jue Lie Kim, Eunwoo Lee, Hyun Chae Jung
Journal of Gastrointestinal Surgery.2020; 24(7): 1499. CrossRef
Clear cell renal carcinoma synchronous with dedifferentiated liposarcoma: a case report and review of the literature
Estefania Beltran, Juan Esteban Garcia-Robledo, Lisa X. Rodríguez-Rojas, Martin Rengifo, Bladimir Perez, Harry Pachajoa, Angela R. Zambrano
Journal of Medical Case Reports.2020;[Epub] CrossRef
Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation
Matthias Guckenberger, Yolande Lievens, Angelique B Bouma, Laurence Collette, Andre Dekker, Nandita M deSouza, Anne-Marie C Dingemans, Beatrice Fournier, Coen Hurkmans, Frédéric E Lecouvet, Icro Meattini, Alejandra Méndez Romero, Umberto Ricardi, Nicola S
The Lancet Oncology.2020; 21(1): e18. CrossRef
Rare heterochronous liver and pancreatic multiple primary cancers: a case report and literature review
Wangjun Zhang, Fan Xiao, Jie Li, Xiaoyu Guo, Zhitao Lin, Zijian Huang, Ning Mao, Bei Sun, Gang Wang
Zeitschrift für Gastroenterologie.2020; 58(11): 1094. CrossRef
Gastric carcinoma and renal cell carcinoma as an atypical presentation of multiple primary malignancies: a case report and review of the literature
J. A. Martín-Pérez, C. Torres-Silva, R. Tenorio-Arguelles, D. A. García-Corona, S. Silva-González, J. A. Dominguez-Rodriguez, I. De Alba-Cruz, J. F. Nagore-Ancona, J. A. González-Luna, K. A. López-Bochm
Journal of Medical Case Reports.2020;[Epub] CrossRef
Helicobacter pylori Eradication for Metachronous Gastric Cancer: An Unsuitable Methodology Impeding Broader Clinical Usage
Alexios-Fotios A. Mentis, Efthimios Dardiotis
Frontiers in Oncology.2019;[Epub] CrossRef
A case report of cholangiocarcinoma combined with moderately differentiated gastric adenocarcinoma
Yan-Hui Yang, Qing Deng, Tian-Bao Yang, Yang Gui, Yu-xiang Zhang, Jiang-Bo Liu, Qian Deng, Wei-Feng Liu, Jun-Jun Sun
Medicine.2019; 98(30): e16332. CrossRef
Management and Follow-up of Patients with a Bronchial Neuroendocrine Tumor in the Last Twenty Years in Ireland: Expected Inconsistencies and Unexpected Discoveries
Asta Agasarova, Clare Harnett, Niall Mulligan, Muhammad Shakeel Majeed, Alberto Caimo, Gianluca Tamagno
International Journal of Endocrinology.2018; 2018: 1. CrossRef
Clinicopathologic characteristics and survival rate in patients with synchronous or metachronous double primary colorectal and gastric cancer
Ji-Hyeon Park, Jeong-Heum Baek, Jun-Young Yang, Won-Suk Lee, Woon-Kee Lee
Korean Journal of Clinical Oncology.2018; 14(2): 83. CrossRef
Synchronous primary of periampullary and lung cancer: A case report and review of literature
Vikas Talreja, Vanita Noronha, Amit Joshi, Vijay Patil, Kumar Prabhash
Cancer Research, Statistics, and Treatment.2018; 1(2): 173. CrossRef
Synchronous occurrence of hereditary gastric adenocarcinoma, gastrointestinal stromal tumor, and esophageal small cell and squamous carcinoma in situ: an extremely rare case report
Huijie Fan, Pei Lu, Li Xu, Yanru Qin, Jing Li
BMC Cancer.2017;[Epub] CrossRef
Multiple primary malignancies involving lung cancer
Feng Li, Wen-Zhao Zhong, Fei-Yu Niu, Ning Zhao, Jin-Ji Yang, Hong-Hong Yan, Yi-Long Wu
BMC Cancer.2015;[Epub] CrossRef
Limitations of PET and PET/CT in detecting upper gastrointestinal synchronous cancer in patients with head and neck carcinoma
Kenichiro Yabuki, Akira Kubota, Choichi Horiuchi, Takahide Taguchi, Goshi Nishimura, Masahiko Inamori
European Archives of Oto-Rhino-Laryngology.2013; 270(2): 727. CrossRef

12,471 View
98 Download
27 Crossref

Case Report

Novel Sunitinib Strategy in Metastatic Renal Cell Carcinoma on Hemodialysis: Intermittent Dose of Sunitinib after Hemodialysis: Sang Hyun Yoon, Ki Hyang Kim, Junjeong Choi, Gun Min Kim, Joo Hoon Kim, Hyo Song Kim, Young Nyun Park, Sun Young Rha; Cancer Res Treat. 2010;42(3):180-184. Published online September 30, 2010; DOI: https://doi.org/10.4143/crt.2010.42.3.180

Abstract PDF PubReader ePub

The proper dose and schedule of sunitinib have yet to be established for patients with metastatic renal cell carcinoma (RCC) on hemodialysis. We reviewed two patients with metastatic RCC on hemodialysis who had been treated with sunitinib in Yonsei Cancer Center, Yonsei University College of Medicine. Fifty milligrams of sunitinib was administered intermittently after each hemodialysis session (3 or 4 times a week). Overall responses were partial response in both cases. Progression-free survivals were 16 and 6 months, respectively, at the time of reporting (April 2010). Both subjects tolerated the treatment.

Citations

Citations to this article as recorded by

Targeted and immune therapies among patients with metastatic renal carcinoma undergoing hemodialysis: A systemic review
Elodie Klajer, Louis Garnier, Morgan Goujon, Friederike Schlurmann-Constans, Benoite Mery, Thierry Nguyen Tan Hon, Guillaume Mouillet, Fabien Calcagno, Antoine Thiery-Vuillemin
Seminars in Oncology.2020; 47(2-3): 103. CrossRef
Targeted Agents in Patients with Metastatic Renal Cell Carcinoma on Dialysis: Myths and Reality
Annalisa Guida, Laura Cosmai, Fabio Gelsomino, Cristina Masini, Roberto Sabbatini, Camillo Porta
EMJ Nephrology.2016; : 66. CrossRef
Recent Aspects of Sunitinib Therapy in Patients with Metastatic Clear-Cell Renal Cell Carcinoma: a Systematic Review of the Literature
Daniele Minardi, Luigi Quaresima, Matteo Santoni, Maristella Bianconi, Mario Scartozzi, Stefano Cascinu, Giovanni Muzzonigro
Current Urology Reports.2015;[Epub] CrossRef
Feasibility, Efficacy and Safety of Tyrosine Kinase Inhibitor Treatment in Hemodialyzed Patients with Renal Cell Cancer: 10 Years of Experience
Anna M Czarnecka, Maciej Kawecki, Fei Lian, Jan Korniluk, Cezary Szczylik
Future Oncology.2015; 11(16): 2267. CrossRef
Efficacy and toxicity of sunitinib in patients with metastatic renal cell carcinoma with renal insufficiency
Ki Hyang Kim, Ho Young Kim, Hye Ryun Kim, Jong-Mu Sun, Ho Yeong Lim, Hyo Jin Lee, Suee Lee, Woo Kyun Bae, Sun Young Rha
European Journal of Cancer.2014; 50(4): 746. CrossRef
Intolerance to Sunitinib Treatment in Hemodialysis Patients With Metastatic Renal Cell Carcinoma
Ibrahim Yildiz, Fatma Sen, Leyla Kilic, Rumeysa Ciftci, Mert Basaran
Korean Journal of Urology.2014; 55(1): 74. CrossRef
A contemporary update on rates and management of toxicities of targeted therapies for metastatic renal cell carcinoma
Ahmed Alasker, Malek Meskawi, Maxine Sun, Salima Ismail, Nawar Hanna, Jens Hansen, Zhe Tian, Marco Bianchi, Paul Perrotte, Pierre I. Karakiewicz
Cancer Treatment Reviews.2013; 39(4): 388. CrossRef
Use of tyrosine kinase inhibitors in patients with metastatic kidney cancer receiving haemodialysis: a retrospective Italian survey
Cristina Masini, Roberto Sabbatini, Camillo Porta, Giuseppe Procopio, Giuseppe Di Lorenzo, Azzurra Onofri, Sebastiano Buti, Roberto Iacovelli, Roberta Invernizzi, Luca Moscetti, Maria Giuseppina Aste, Maria Pagano, Federica Grosso, Anna Lucia Manenti, Cin
BJU International.2012; 110(5): 692. CrossRef

10,304 View
67 Download
8 Crossref

Original Article

Wernicke's Encephalopathy in Advanced Gastric Cancer: Eun Suk Jung, Obin Kwon, Soo Hyun Lee, Ki Byung Lee, Joo Hoon Kim, Sang Hyun Yoon, Gun Min Kim, Hei-Cheul Jeung, Sun Young Rha; Cancer Res Treat. 2010;42(2):77-81. Published online June 30, 2010; DOI: https://doi.org/10.4143/crt.2010.42.2.77

Abstract PDF PubReader ePub

Purpose

With their prolonged survival and malnutrition, cancer patients, and especially gastrointestinal (GI) tract cancer patients, can develop Wernicke's encephalopathy (WE). The aim of this study is to remind physicians of the importance of WE and prompt management in patients with GI tract cancer.

Materials and Methods

This study is a retrospective review of 2 cases of WE in advanced gastric cancer (AGC) patients, and we review the literature for cases of GI tract cancer related to WE.

Results

A 48-year-old female with AGC presented dizziness and diplopia for 5 days and a 20 kg weight loss. Neurologic exam showed nystagmus and gaze disturbance. Her symptoms improved after daily parenteral injection of thiamine 100 mg for 17 days. A 58-year-old female with AGC presented with sudden disorientation, confusion and 15 kg weight loss. Neurologic exam showed gaze limitation and mild ataxia. Despite daily parenteral injection of thiamine 100 mg for 4 days, she died 5 days after the onset of neurologic symptoms. Combining the cases noted in the literature review with our 2 cases, the 7 gastric cancer cases and 2 colorectal cancer cases related to WE showed similar clinical characteristics; 1) a history of long-period malnutrition and weight loss, 2) relatively typical neurologic signs and symptoms and 3) specific magnetic resonance image findings. Except for 2 patients who had irreversible neurologic symptoms, the other 7 patients were improved with prompt thiamine treatment.

Conclusion

It is important to consider WE in GI tract cancer patients with acute neurologic symptoms and who are in a state of malnutrition. Thiamine should be given as soon as possible when WE is suspected.

Citations

Citations to this article as recorded by

Duodenal Adenocarcinoma in the Setting of Bariatric Surgery: A Perfect Storm for Wernicke’s Encephalopathy
Aliza Gross, Allen T Yu, Jacques Lara-Reyna, Koji Park, Eugenius J Harvey
Cureus.2023;[Epub] CrossRef
Thiamine deficiency in pregnancy and lactation: implications and present perspectives
Ozaifa Kareem, Sobia Nisar, Masood Tanvir, Umar Muzaffer, G. N. Bader
Frontiers in Nutrition.2023;[Epub] CrossRef
Beware of lethal Wernicke's encephalopathy after cytoreductive surgery with HIPEC for peritoneal pseudomyxoma: Case report of morbidity and mortality review
Oumayma Lahnaoui, Nezha EL Bahaoui, Sara El Atiq, Laila Amrani, Mohammed Anass Majbar, Amine Benkabbou, Raouf Mohsine, Amine Souadka
International Journal of Surgery Case Reports.2022; 98: 107500. CrossRef
Thiamine deficiency unrelated to alcohol consumption in high‐income countries: a literature review
Filomena Gomes, Gilles Bergeron, Megan W. Bourassa, Philip R. Fischer
Annals of the New York Academy of Sciences.2021; 1498(1): 46. CrossRef
WERNICKE ENCEPHALOPATHY IN A PATIENT WITH GASTRIC CANCER RECURRENCE AFTER UPPER GASTROINTESTINAL SURGERY: A CASE REPORT AND REVIEW OF THE LITERATURE
Zining Liu, Xin Ye, Jiejin Yang, Zeyang Chen
Gastroenterology Nursing.2020; 43(6): 463. CrossRef
Wernicke's encephalopathy in a subject with enter-colic fistula
Daniele Canova, Paola Scalon, Fabio Monica, Stefano A. Grassi, Anna Giacomin, Tiziana Tumelero, Gaetano Mastropaolo, Francesco Malfa
Gazzetta Medica Italiana Archivio per le Scienze Mediche.2019;[Epub] CrossRef
Wernicke's encephalopathy in a patient with non-Hodgkin's lymphoma post-Autologous HSCT
João Paulo de Vasconcelos Leitão, Romélia Pinheiro Gonçalves Lemes, Maritza Cavalcante Barbosa, Beatriz Stela Gomes de Souza Pitombeira Araújo, Karine Sampaio Nunes Barroso, Jacques Kaufman, Talyta Ellen de Jesus dos Santos, Anna Thawanny Gadelha Moura, A
Revista da Associação Médica Brasileira.2018; 64(10): 882. CrossRef
Wernicke encephalopathy as initial presentation of lymphoma
Ju Hyun Seo, Ju Hee Kim, Der Sheng Sun, Hye Sung Won, Jeong Wook Park, Yoon Ho Ko
The Korean Journal of Internal Medicine.2017; 32(6): 1112. CrossRef
The Role of Thiamine and Effects of Deficiency in Dogs and Cats
Georgia Kritikos, Jacqueline Parr, Adronie Verbrugghe
Veterinary Sciences.2017; 4(4): 59. CrossRef
Association between malignancy and non-alcoholic Wernicke's encephalopathy: a case report and literature review
Evan Y. Choi, William A. Gomes, Missak Haigentz, Jerome J. Graber
Neuro-Oncology Practice.2016; 3(3): 196. CrossRef
Wernicke encephalopathy as rare complication of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy
Antonio Macrì, Francesco Fleres, Antonio Ieni, Maurizio Rossitto, Tommaso Mandolfino, Salvatore Micalizzi, Francesco Iaropoli, Carmelo Mazzeo, Massimo Trovato, Eugenio Cucinotta, Edoardo Saladino
International Journal of Surgery Case Reports.2015; 16: 29. CrossRef
Two Cases of Wernicke's Encephalopathy That Developed during Total Parenteral Nutrition in Colon Cancer Patients Treated with 5-Fluorouracil-based Chemotherapy
Kyung Pyo Cho, Jae Sung Lee, Ji Seok Seong, Yong Moon Woo, Young Jun Cho, Beom Jin Jeong, Jee Hoon Sohn, Su-Jung Kim
The Korean Journal of Gastroenterology.2014; 64(3): 158. CrossRef
Wernicke's encephalopathy in a patient with gastric carcinoma: a diagnosis not to miss
Chandrashekar Udyavara Kudru, Shivashankara Kaniyoor Nagiri, Sandeep Rao
BMJ Case Reports.2014; : bcr2013203511. CrossRef
Wernicke-Korsakoff Syndrome in Primary Peritoneal Cancer
Ki Hyang Kim
Case Reports in Oncology.2013; 6(3): 593. CrossRef

12,247 View
86 Download
14 Crossref

First
Prev
Page of 1
Next
Last

Search